##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	77	77	.	+	.	ID=ID_0;Name=g.T-189C;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T-189C;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF1ab;aa_name=;mutation_type=;ao=1;Variant_seq=C;ro=171;mat_pep_acc=;dp=172;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005813953488372093;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	177	177	.	+	.	ID=ID_1;Name=g.T-89C;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T-89C;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF1ab;aa_name=;mutation_type=;ao=36;Variant_seq=C;ro=147;mat_pep_acc=;dp=183;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.19672131147540983;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_2;Name=g.C-25A;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C-25A;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF1ab;aa_name=;mutation_type=;ao=36;Variant_seq=A;ro=0;mat_pep_acc=;dp=183;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.19672131147540983;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_3;Name=g.C-25T;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C-25T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF1ab;aa_name=;mutation_type=;ao=147;Variant_seq=T;ro=0;mat_pep_acc=;dp=183;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8032786885245902;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	448	448	.	+	.	ID=ID_4;Name=L61F;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G183T;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.L61F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	498	498	.	+	.	ID=ID_5;Name=T78I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C233T;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.T78I;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	507	507	.	+	.	ID=ID_6;Name=M85I;Reference_seq=ATGGTCATGTTATGGTT;ps_exc=;ps_filter=;nt_name=g.G255A;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.M85I;mutation_type=MISSENSE;ao=3;Variant_seq=AT;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015873015873015872;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	507	507	.	+	.	ID=ID_7;Name=M85_V86del;Reference_seq=ATGGTCATGTTATGGTT;ps_exc=;ps_filter=;nt_name=g.253_258delATGGTT;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.M85_V86del;mutation_type=;ao=2;Variant_seq=ATGTGGTT;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	507	507	.	+	.	ID=ID_8;Name=G82_M85delinsV;Reference_seq=ATGGTCATGTTATGGTT;ps_exc=;ps_filter=;nt_name=g.245_253delGTCATGTTA;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.G82_M85delinsV;mutation_type=;ao=1;Variant_seq=ATGGTCATGTT;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	507	507	.	+	.	ID=ID_9;Name=G82_V86del;Reference_seq=ATGGTCATGTTATGGTT;ps_exc=;ps_filter=;nt_name=g.245_259delGTCATGTTATGGTTG;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.G82_V86del;mutation_type=;ao=1;Variant_seq=ATGGTCATGTTATAGTT;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	565	565	.	+	.	ID=ID_10;Name=S100R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T300A;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.S100R;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	635	635	.	+	.	ID=ID_11;Name=R124C;Reference_seq=C;ps_exc=highly_ambiguous,homoplasic,narrow_src;ps_filter=mask;nt_name=g.C370T;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.R124C;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	670	670	.	+	.	ID=ID_12;Name=S135R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T405G;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.S135R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	799	799	.	+	.	ID=ID_13;Name=N178N;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C534T;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_id=leader protein;vcf_gene=ORF1ab;aa_name=p.N178N;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP1;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	843	843	.	+	.	ID=ID_14;Name=P193H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C578A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.P193H;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	889	889	.	+	.	ID=ID_15;Name=A208A;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T624C;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.A208A;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	943	943	.	+	.	ID=ID_16;Name=R226R;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G678A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.R226R;mutation_type=SILENT;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1127	1127	.	+	.	ID=ID_17;Name=V288F;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G862T;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.V288F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1466	1466	.	+	.	ID=ID_18;Name=G401S;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1201A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.G401S;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1693	1693	.	+	.	ID=ID_19;Name=I476I;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1428C;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.I476I;mutation_type=SILENT;ao=31;Variant_seq=C;ro=148;mat_pep_acc=;dp=179;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.17318435754189945;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1710	1710	.	+	.	ID=ID_20;Name=A482D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1445A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.A482D;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=178;mat_pep_acc=;dp=179;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00558659217877095;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1714	1714	.	+	.	ID=ID_21;Name=S483S;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1449A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.S483S;mutation_type=SILENT;ao=1;Variant_seq=A;ro=178;mat_pep_acc=;dp=179;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00558659217877095;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	1931	1931	.	+	.	ID=ID_22;Name=Q556K;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1666A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.Q556K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2127	2127	.	+	.	ID=ID_23;Name=Y621C;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1862G;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.Y621C;mutation_type=MISSENSE;ao=7;Variant_seq=G;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.037037037037037035;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2153	2153	.	+	.	ID=ID_24;Name=W630R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1888C;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.W630R;mutation_type=MISSENSE;ao=36;Variant_seq=C;ro=153;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.19047619047619047;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2462	2462	.	+	.	ID=ID_25;Name=L733L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2197T;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.L733L;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2523	2523	.	+	.	ID=ID_26;Name=T753I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2258T;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp2;vcf_gene=ORF1ab;aa_name=p.T753I;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP2;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2790	2790	.	+	.	ID=ID_27;Name=T842I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2525T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.T842I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	2954	2954	.	+	.	ID=ID_28;Name=L897L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2689C;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.L897L;mutation_type=SILENT;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	3031	3031	.	+	.	ID=ID_29;Name=C922C;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2766C;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.C922C;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_30;Name=F924F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2772T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.F924F;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	3055	3055	.	+	.	ID=ID_31;Name=D930D;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2790C;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.D930D;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	3276	3276	.	+	.	ID=ID_32;Name=T1004I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C3011T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.T1004I;mutation_type=MISSENSE;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	3546	3546	.	+	.	ID=ID_33;Name=G1095_C1103del;Reference_seq=ATGGACCACTTAAAGTGGGTGGTAGTTGT;ps_exc=;ps_filter=;nt_name=g.3284_3310delGACCACTTAAAGTGGGTGGTAGTTGTG;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.G1095_C1103del;mutation_type=;ao=2;Variant_seq=AT;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	4012	4012	.	+	.	ID=ID_34;Name=L1249L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C3747T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.L1249L;mutation_type=SILENT;ao=2;Variant_seq=T;ro=181;mat_pep_acc=;dp=183;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01092896174863388;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	4184	4184	.	+	.	ID=ID_35;Name=G1307S;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G3919A;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.G1307S;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	4321	4321	.	+	.	ID=ID_36;Name=A1352A;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C4056T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.A1352A;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	4528	4528	.	+	.	ID=ID_37;Name=R1421R;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A4263G;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.R1421R;mutation_type=SILENT;ao=14;Variant_seq=G;ro=66;mat_pep_acc=;dp=80;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.175;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	5413	5413	.	+	.	ID=ID_38;Name=A1716A;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C5148T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.A1716A;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	5512	5512	.	+	.	ID=ID_39;Name=N1749N;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C5247T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.N1749N;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	5533	5533	.	+	.	ID=ID_40;Name=G1756G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A5268G;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.G1756G;mutation_type=SILENT;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	5646	5646	.	+	.	ID=ID_41;Name=T1794I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C5381T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.T1794I;mutation_type=MISSENSE;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	6027	6027	.	+	.	ID=ID_42;Name=P1921L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C5762T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.P1921L;mutation_type=MISSENSE;ao=5;Variant_seq=T;ro=184;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026455026455026454;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	6106	6106	.	+	.	ID=ID_43;Name=Y1947Y;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T5841C;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.Y1947Y;mutation_type=SILENT;ao=2;Variant_seq=C;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	6426	6426	.	+	.	ID=ID_44;Name=N2054S;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A6161G;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.N2054S;mutation_type=MISSENSE;ao=10;Variant_seq=G;ro=177;mat_pep_acc=;dp=187;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.053475935828877004;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	6531	6531	.	+	.	ID=ID_45;Name=E2089G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A6266G;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.E2089G;mutation_type=MISSENSE;ao=8;Variant_seq=G;ro=178;mat_pep_acc=;dp=186;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043010752688172046;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	6926	6926	.	+	.	ID=ID_46;Name=P2221S;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C6661T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.P2221S;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	7011	7011	.	+	.	ID=ID_47;Name=A2249V;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C6746T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.A2249V;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	7320	7320	.	+	.	ID=ID_48;Name=S2352N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G7055A;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.S2352N;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	7393	7393	.	+	.	ID=ID_49;Name=P2376P;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G7128T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.P2376P;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	7420	7420	.	+	.	ID=ID_50;Name=I2385I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C7155T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.I2385I;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	7851	7851	.	+	.	ID=ID_51;Name=A2529V;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C7586T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.A2529V;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8146	8146	.	+	.	ID=ID_52;Name=D2627D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C7881T;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.D2627D;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8161	8161	.	+	.	ID=ID_53;Name=T2632T;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T7896C;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.T2632T;mutation_type=SILENT;ao=11;Variant_seq=C;ro=178;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0582010582010582;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8461	8461	.	+	.	ID=ID_54;Name=A2732A;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T8196A;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_id=nsp3;vcf_gene=ORF1ab;aa_name=p.A2732A;mutation_type=SILENT;ao=8;Variant_seq=A;ro=181;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP3;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.042328042328042326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8848	8848	.	+	.	ID=ID_55;Name=E2861E;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A8583G;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.E2861E;mutation_type=SILENT;ao=5;Variant_seq=G;ro=183;mat_pep_acc=;dp=188;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026595744680851064;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8905	8905	.	+	.	ID=ID_56;Name=D2880D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C8640T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.D2880D;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	8917	8917	.	+	.	ID=ID_57;Name=F2884F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C8652T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.F2884F;mutation_type=SILENT;ao=36;Variant_seq=T;ro=153;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.19047619047619047;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9344	9344	.	+	.	ID=ID_58;Name=L3027F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9079T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.L3027F;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9424	9424	.	+	.	ID=ID_59;Name=V3053V;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A9159G;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.V3053V;mutation_type=SILENT;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9521	9521	.	+	.	ID=ID_60;Name=L3086F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9256T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.L3086F;mutation_type=MISSENSE;ao=11;Variant_seq=T;ro=178;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0582010582010582;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9534	9534	.	+	.	ID=ID_61;Name=T3090I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9269T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.T3090I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9700	9700	.	+	.	ID=ID_62;Name=I3145I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9435T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.I3145I;mutation_type=SILENT;ao=13;Variant_seq=T;ro=176;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06878306878306878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9857	9857	.	+	.	ID=ID_63;Name=L3198L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9592T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.L3198L;mutation_type=SILENT;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	9929	9929	.	+	.	ID=ID_64;Name=D3222N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G9664A;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.D3222N;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10029	10029	.	+	.	ID=ID_65;Name=T3255I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9764T;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_id=nsp4;vcf_gene=ORF1ab;aa_name=p.T3255I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP4;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10135	10135	.	+	.	ID=ID_66;Name=L3290L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T9870A;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.L3290L;mutation_type=SILENT;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10138	10138	.	+	.	ID=ID_67;Name=N3291N;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9873T;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.N3291N;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10171	10171	.	+	.	ID=ID_68;Name=P3302P;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A9906G;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.P3302P;mutation_type=SILENT;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10198	10198	.	+	.	ID=ID_69;Name=D3311D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C9933T;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.D3311D;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	10296	10296	.	+	.	ID=ID_70;Name=S3344F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C10031T;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.S3344F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	10447	10447	.	+	.	ID=ID_71;Name=P3395H;Reference_seq=GCC;ps_exc=;ps_filter=;nt_name=g.GCC10182_10184ACA;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_id=3C-like proteinase;vcf_gene=ORF1ab;aa_name=p.P3395H;mutation_type=;ao=189;Variant_seq=ACA;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP5;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	11074	11074	.	+	.	ID=ID_72;Name=L3606F;Reference_seq=CTTTTTTTTGTATGA;ps_exc=;ps_filter=;nt_name=g.G10818T;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_id=nsp6;vcf_gene=ORF1ab;aa_name=p.L3606F;mutation_type=MISSENSE;ao=1;Variant_seq=CTTTTTTTTTTTTTATGA;ro=180;mat_pep_acc=;dp=188;chrom_region=ORF1a;protein=NSP6;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005319148936170213;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	11074	11074	.	+	.	ID=ID_73;Name=L3606delinsFF;Reference_seq=CTTTTTTTTGTATGA;ps_exc=;ps_filter=;nt_name=g.G10818TTTT;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_id=nsp6;vcf_gene=ORF1ab;aa_name=p.L3606delinsFF;mutation_type=;ao=2;Variant_seq=TTTTTTTTTGTATGA;ro=180;mat_pep_acc=;dp=188;chrom_region=ORF1a;protein=NSP6;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010638297872340425;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	11074	11074	.	+	.	ID=ID_74;Name=F3603F;Reference_seq=CTTTTTTTTGTATGA;ps_exc=;ps_filter=;nt_name=g.C10809T;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_id=nsp6;vcf_gene=ORF1ab;aa_name=p.F3603F;mutation_type=SILENT;ao=5;Variant_seq=CTTTTTTTTTTATGA;ro=180;mat_pep_acc=;dp=188;chrom_region=ORF1a;protein=NSP6;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026595744680851064;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	11750	11750	.	+	.	ID=ID_75;Name=L3829F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C11485T;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_id=nsp6;vcf_gene=ORF1ab;aa_name=p.L3829F;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP6;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	12160	12160	.	+	.	ID=ID_76;Name=E3965E;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G11895A;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_id=nsp8;vcf_gene=ORF1ab;aa_name=p.E3965E;mutation_type=SILENT;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP8;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	12880	12880	.	+	.	ID=ID_77;Name=I4205I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C12615T;mat_pep_desc=ssRNA-binding protein, produced by both pp1a and pp1ab;mat_pep_id=nsp9;vcf_gene=ORF1ab;aa_name=p.I4205I;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP9;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	13370	13370	.	+	.	ID=ID_78;Name=V4369I;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G13105A;mat_pep_desc=nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab;mat_pep_id=nsp10;vcf_gene=ORF1ab;aa_name=p.V4369I;mutation_type=MISSENSE;ao=6;Variant_seq=A;ro=183;mat_pep_acc=;dp=189;chrom_region=ORF1a;protein=NSP10;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.031746031746031744;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	13710	13710	.	+	.	ID=ID_79;Name=L4482L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T13446C;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.L4482L;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	14257	14257	.	+	.	ID=ID_80;Name=Y4665H;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T13993C;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.Y4665H;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_81;Name=P4715L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C14144T;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.P4715L;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	14688	14688	.	+	.	ID=ID_82;Name=N4808N;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C14424T;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.N4808N;mutation_type=SILENT;ao=5;Variant_seq=T;ro=184;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026455026455026454;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	14718	14718	.	+	.	ID=ID_83;Name=K4818K;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G14454A;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.K4818K;mutation_type=SILENT;ao=2;Variant_seq=A;ro=176;mat_pep_acc=;dp=178;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011235955056179775;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	14937	14937	.	+	.	ID=ID_84;Name=D4891D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C14673T;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.D4891D;mutation_type=SILENT;ao=42;Variant_seq=T;ro=145;mat_pep_acc=;dp=187;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.22459893048128343;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	15324	15324	.	+	.	ID=ID_85;Name=N5020N;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C15060T;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.N5020N;mutation_type=SILENT;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	15714	15714	.	+	.	ID=ID_86;Name=L5150L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C15450T;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_id=RNA-dependent RNA polymerase;vcf_gene=ORF1ab;aa_name=p.L5150L;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP12;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	16935	16935	.	+	.	ID=ID_87;Name=M5557I;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G16671A;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.M5557I;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17019	17019	.	+	.	ID=ID_88;Name=E5585D;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G16755T;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.E5585D;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17039	17039	.	+	.	ID=ID_89;Name=N5592S;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A16775G;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.N5592S;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17193	17193	.	+	.	ID=ID_90;Name=E5643D;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G16929T;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.E5643D;mutation_type=MISSENSE;ao=7;Variant_seq=T;ro=182;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.037037037037037035;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17340	17340	.	+	.	ID=ID_91;Name=A5692A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A17076C;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.A5692A;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17410	17410	.	+	.	ID=ID_92;Name=R5716C;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C17146T;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.R5716C;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17574	17574	.	+	.	ID=ID_93;Name=A5770A;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T17310C;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.A5770A;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	17822	17822	.	+	.	ID=ID_94;Name=P5853L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C17558T;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_id=helicase;vcf_gene=ORF1ab;aa_name=p.P5853L;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP13;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	18163	18163	.	+	.	ID=ID_95;Name=I5967V;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A17899G;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_id=3'-to-5' exonuclease;vcf_gene=ORF1ab;aa_name=p.I5967V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP14;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	18383	18383	.	+	.	ID=ID_96;Name=V6040A;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T18119C;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_id=3'-to-5' exonuclease;vcf_gene=ORF1ab;aa_name=p.V6040A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP14;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	18431	18431	.	+	.	ID=ID_97;Name=T6056I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C18167T;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_id=3'-to-5' exonuclease;vcf_gene=ORF1ab;aa_name=p.T6056I;mutation_type=MISSENSE;ao=2;Variant_seq=T;ro=186;mat_pep_acc=;dp=188;chrom_region=ORF1b;protein=NSP14;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010638297872340425;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	18877	18877	.	+	.	ID=ID_98;Name=L6205L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C18613T;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_id=3'-to-5' exonuclease;vcf_gene=ORF1ab;aa_name=p.L6205L;mutation_type=SILENT;ao=34;Variant_seq=T;ro=155;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP14;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.17989417989417988;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	18970	18970	.	+	.	ID=ID_99;Name=K6236E;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A18706G;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_id=3'-to-5' exonuclease;vcf_gene=ORF1ab;aa_name=p.K6236E;mutation_type=MISSENSE;ao=140;Variant_seq=G;ro=49;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP14;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.7407407407407407;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	19955	19955	.	+	.	ID=ID_100;Name=T6564I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C19691T;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_id=endoRNAse;vcf_gene=ORF1ab;aa_name=p.T6564I;mutation_type=MISSENSE;ao=184;Variant_seq=T;ro=0;mat_pep_acc=;dp=184;chrom_region=ORF1b;protein=NSP15;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	19983	19983	.	+	.	ID=ID_101;Name=V6573V;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C19719T;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_id=endoRNAse;vcf_gene=ORF1ab;aa_name=p.V6573V;mutation_type=SILENT;ao=1;Variant_seq=T;ro=186;mat_pep_acc=;dp=187;chrom_region=ORF1b;protein=NSP15;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	20055	20055	.	+	.	ID=ID_102;Name=E6597E;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A19791G;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_id=endoRNAse;vcf_gene=ORF1ab;aa_name=p.E6597E;mutation_type=SILENT;ao=186;Variant_seq=G;ro=0;mat_pep_acc=;dp=186;chrom_region=ORF1b;protein=NSP15;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	20199	20199	.	+	.	ID=ID_103;Name=Y6645Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C19935T;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_id=endoRNAse;vcf_gene=ORF1ab;aa_name=p.Y6645Y;mutation_type=SILENT;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP15;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	20806	20806	.	+	.	ID=ID_104;Name=L6848L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C20542T;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.L6848L;mutation_type=SILENT;ao=13;Variant_seq=T;ro=176;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06878306878306878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	20982	20982	.	+	.	ID=ID_105;Name=D6906D;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T20718C;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.D6906D;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21059	21059	.	+	.	ID=ID_106;Name=P6932L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C20795T;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.P6932L;mutation_type=MISSENSE;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21128	21128	.	+	.	ID=ID_107;Name=I6955T;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T20864C;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.I6955T;mutation_type=MISSENSE;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21137	21137	.	+	.	ID=ID_108;Name=K6958R;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A20873G;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.K6958R;mutation_type=MISSENSE;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21191	21191	.	+	.	ID=ID_109;Name=A6976V;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C20927T;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.A6976V;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21255	21255	.	+	.	ID=ID_110;Name=A6997A;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G20991A;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_id=2'-O-ribose methyltransferase;vcf_gene=ORF1ab;aa_name=p.A6997A;mutation_type=SILENT;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF1b;protein=NSP16;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_111;Name=L5F;Reference_seq=C;ps_exc=highly_homoplasic;ps_filter=mask;nt_name=g.C13T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L5F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_111;Name=L5F;Reference_seq=C;ps_exc=highly_homoplasic;ps_filter=mask;nt_name=g.C13T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L5F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_111;Name=L5F;Reference_seq=C;ps_exc=highly_homoplasic;ps_filter=mask;nt_name=g.C13T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L5F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21618	21618	.	+	.	ID=ID_112;Name=T19I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C56T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.T19I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	21632	21632	.	+	.	ID=ID_113;Name=L24_A27delinsS;Reference_seq=TTACCCCCTGC;ps_exc=;ps_filter=;nt_name=g.71_79delTACCCCCTG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L24_A27delinsS;mutation_type=;ao=189;Variant_seq=TC;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21794	21794	.	+	.	ID=ID_114;Name=R78G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A232G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.R78G;mutation_type=MISSENSE;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	21981	21981	.	+	.	ID=ID_115;Name=G142D;Reference_seq=TTTTGGGTGTTTATTAC;ps_exc=;ps_filter=;nt_name=g.G425A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G142D;mutation_type=MISSENSE;ao=2;Variant_seq=TTTTGGATGTTTAC;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010638297872340425;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	21981	21981	.	+	.	ID=ID_115;Name=G142D;Reference_seq=TTTTGGGTGTTTATTAC;ps_exc=;ps_filter=;nt_name=g.G425A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G142D;mutation_type=MISSENSE;ao=2;Variant_seq=TTTTGGATGTTTAC;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010638297872340425;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1;citation=Suryadevara et al. (2021);comb_mutation=;function_description=Selected twice in passage with mAb COV2-2489.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	21981	21981	.	+	.	ID=ID_116;Name=G142_Y144delinsDV;Reference_seq=TTTTGGGTGTTTATTAC;ps_exc=;ps_filter=;nt_name=g.GTGTTTA425_431ATGT;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G142_Y144delinsDV;mutation_type=;ao=1;Variant_seq=TTTAC;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005319148936170213;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	21981	21981	.	+	.	ID=ID_117;Name=L141_Y144del;Reference_seq=TTTTGGGTGTTTATTAC;ps_exc=;ps_filter=;nt_name=g.422_433delTGGGTGTTTATT;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L141_Y144del;mutation_type=;ao=185;Variant_seq=TTTTGGATGTTTATTAC;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9840425531914894;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22200	22200	.	+	.	ID=ID_118;Name=V213G;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T638G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.V213G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22376	22376	.	+	.	ID=ID_119;Name=P272S;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C814T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P272S;mutation_type=MISSENSE;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22578	22578	.	+	.	ID=ID_120;Name=G339D;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1016A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G339D;mutation_type=MISSENSE;ao=186;Variant_seq=A;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22578	22578	.	+	.	ID=ID_120;Name=G339D;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1016A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G339D;mutation_type=MISSENSE;ao=186;Variant_seq=A;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.3 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_121;Name=R346T;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1037C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.R346T;mutation_type=MISSENSE;ao=186;Variant_seq=C;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_121;Name=R346T;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1037C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.R346T;mutation_type=MISSENSE;ao=186;Variant_seq=C;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22674	22674	.	+	.	ID=ID_122;Name=S371F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1112T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.S371F;mutation_type=MISSENSE;ao=184;Variant_seq=T;ro=0;mat_pep_acc=;dp=184;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22679	22679	.	+	.	ID=ID_123;Name=S373P;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1117C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.S373P;mutation_type=MISSENSE;ao=184;Variant_seq=C;ro=0;mat_pep_acc=;dp=184;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1128/mBio.02707-20;citation=Long et al. (2020);comb_mutation=;function_description=Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22686	22686	.	+	.	ID=ID_124;Name=ST375FA;Reference_seq=CCA;ps_exc=;ps_filter=;nt_name=g.CCA1124_1126TCG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.ST375FA;mutation_type=;ao=184;Variant_seq=TCG;ro=0;mat_pep_acc=;dp=184;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22775	22775	.	+	.	ID=ID_125;Name=D405N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1213A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D405N;mutation_type=MISSENSE;ao=186;Variant_seq=A;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22786	22786	.	+	.	ID=ID_126;Name=R408S;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1224C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.R408S;mutation_type=MISSENSE;ao=185;Variant_seq=C;ro=0;mat_pep_acc=;dp=185;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_128;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_128;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_129;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_130;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='N501Y';function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_128;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_128;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_129;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (911 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_127;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_128;Name=K417N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1251T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K417N;mutation_type=MISSENSE;ao=188;Variant_seq=T;ro=0;mat_pep_acc=;dp=188;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22844	22844	.	+	.	ID=ID_131;Name=D428Y;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G1282T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D428Y;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=antibody epitope effects;source=https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1;citation=Tandel et al. (2021);comb_mutation=;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22879	22879	.	+	.	ID=ID_133;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.T1320G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=MISSENSE;ao=33;Variant_seq=TAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1746031746031746;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation='D614G';function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=antibody epitope effects;source=https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1;citation=Tandel et al. (2021);comb_mutation=;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_132;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22879	22879	.	+	.	ID=ID_133;Name=N440K;Reference_seq=CAAT;ps_exc=;ps_filter=;nt_name=g.CAAT1317_1320TAAG;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N440K;mutation_type=;ao=156;Variant_seq=CAAG;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8253968253968254;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation='D614G';function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22893	22893	.	+	.	ID=ID_134;Name=K444T;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1331C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K444T;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22893	22893	.	+	.	ID=ID_134;Name=K444T;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1331C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.K444T;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.07 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='D614G';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_137;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation='N501Y';function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_135;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_136;Name=L452R;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1355G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L452R;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_138;Name=N460K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1380A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N460K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_138;Name=N460K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1380A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N460K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_138;Name=N460K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1380A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N460K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_138;Name=N460K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1380A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N460K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	22971	22971	.	+	.	ID=ID_139;Name=T470I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1409T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.T470I;mutation_type=MISSENSE;ao=13;Variant_seq=T;ro=176;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06878306878306878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	22992	22992	.	+	.	ID=ID_140;Name=ST477NK;Reference_seq=GCAC;ps_exc=;ps_filter=;nt_name=g.GCAC1430_1433ACAA;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.ST477NK;mutation_type=;ao=189;Variant_seq=ACAA;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23013	23013	.	+	.	"ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_141;Name=E484A;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1451C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.E484A;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_142;Name=F486V;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1456G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.F486V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 88% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_142;Name=F486V;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1456G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.F486V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_142;Name=F486V;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1456G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.F486V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_142;Name=F486V;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1456G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.F486V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_142;Name=F486V;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1456G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.F486V;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.07 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).  Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_129;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_130;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='K417N';function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 g (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_129;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (911 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_137;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation='L452R';function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_143;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1501T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N501Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_145;Name=Y505H;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1513C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.Y505H;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://dx.doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_145;Name=Y505H;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1513C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.Y505H;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23377	23377	.	+	.	ID=ID_146;Name=S605S;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T1815A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.S605S;mutation_type=SILENT;ao=3;Variant_seq=A;ro=186;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015873015873015872;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_149;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H655Y';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_111;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_129;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralnasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='L452R';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='L452R';function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_149;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H655Y';function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_111;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation='L452R';function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_129;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (911 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (911 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationmean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='P681H';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_133;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation='N440K';function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_149;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H655Y';function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_111;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_136;Name=D614G;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1841G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D614G;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L452R';function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_150;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_149;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_150;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_149;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_150;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_149;Name=H655Y;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1963T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.H655Y;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23599	23599	.	+	.	ID=ID_151;Name=N679K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2037G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N679K;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ ;citation=Johnson et al. (2020);comb_mutation=;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_148;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1;citation=Lubinski et al. (2021);comb_mutation=;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_148;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_148;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='D614G';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_152;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_148;Name=P681H;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2042A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.P681H;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23625	23625	.	+	.	ID=ID_153;Name=A688V;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2063T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.A688V;mutation_type=MISSENSE;ao=187;Variant_seq=T;ro=0;mat_pep_acc=;dp=187;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23659	23659	.	+	.	ID=ID_154;Name=L699L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2097C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.L699L;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23854	23854	.	+	.	ID=ID_155;Name=N764K;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2292A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N764K;mutation_type=MISSENSE;ao=186;Variant_seq=A;ro=0;mat_pep_acc=;dp=186;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	23870	23870	.	+	.	ID=ID_156;Name=I770V;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A2308G;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.I770V;mutation_type=MISSENSE;ao=27;Variant_seq=G;ro=155;mat_pep_acc=;dp=182;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.14835164835164835;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24106	24106	.	+	.	ID=ID_157;Name=D848D;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C2544T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D848D;mutation_type=SILENT;ao=1;Variant_seq=T;ro=178;mat_pep_acc=;dp=179;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00558659217877095;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24424	24424	.	+	.	ID=ID_158;Name=Q954H;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A2862T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.Q954H;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24469	24469	.	+	.	ID=ID_159;Name=N969K;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T2907A;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.N969K;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24755	24755	.	+	.	ID=ID_160;Name=V1065L;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G3193C;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.V1065L;mutation_type=MISSENSE;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24933	24933	.	+	.	ID=ID_161;Name=G1124V;Reference_seq=G;ps_exc=highly_ambiguous,highly_homoplasic,narrow_src;ps_filter=mask;nt_name=g.G3371T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.G1124V;mutation_type=MISSENSE;ao=5;Variant_seq=T;ro=184;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026455026455026454;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	24998	24998	.	+	.	ID=ID_162;Name=D1146N;Reference_seq=GAC;ps_exc=;ps_filter=;nt_name=g.GAC3436_3438AAT;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D1146N;mutation_type=;ao=13;Variant_seq=AAT;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06878306878306878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	24998	24998	.	+	.	ID=ID_163;Name=D1146D;Reference_seq=GAC;ps_exc=;ps_filter=;nt_name=g.C3438T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.D1146D;mutation_type=SILENT;ao=176;Variant_seq=GAT;ro=0;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9312169312169312;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25352	25352	.	+	.	ID=ID_164;Name=V1264L;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G3790T;mat_pep_desc=;mat_pep_id=;vcf_gene=S;aa_name=p.V1264L;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=S;protein=spike;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25456	25456	.	+	.	ID=ID_165;Name=D22Y;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G64T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.D22Y;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25469	25469	.	+	.	ID=ID_166;Name=S26L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C77T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.S26L;mutation_type=MISSENSE;ao=12;Variant_seq=T;ro=177;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06349206349206349;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25497	25497	.	+	.	ID=ID_167;Name=I35M;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A105G;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.I35M;mutation_type=MISSENSE;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25507	25507	.	+	.	ID=ID_168;Name=A39T;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G115A;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.A39T;mutation_type=MISSENSE;ao=1;Variant_seq=A;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25546	25546	.	+	.	ID=ID_169;Name=L52F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C154T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.L52F;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25584	25584	.	+	.	ID=ID_170;Name=T64T;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C192T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.T64T;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25614	25614	.	+	.	ID=ID_171;Name=S74S;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C222T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.S74S;mutation_type=SILENT;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	25836	25836	.	+	.	ID=ID_172;Name=C148C;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C444T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.C148C;mutation_type=SILENT;ao=3;Variant_seq=T;ro=186;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015873015873015872;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26013	26013	.	+	.	ID=ID_173;Name=F207F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C621T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.F207F;mutation_type=SILENT;ao=11;Variant_seq=T;ro=178;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0582010582010582;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26060	26060	.	+	.	ID=ID_174;Name=T223I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C668T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF3a;aa_name=p.T223I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF3a;protein=ORF3a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26270	26270	.	+	.	ID=ID_175;Name=T9I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C26T;mat_pep_desc=;mat_pep_id=;vcf_gene=E;aa_name=p.T9I;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=E;protein=E;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26529	26529	.	+	.	ID=ID_176;Name=D3N;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G7A;mat_pep_desc=;mat_pep_id=;vcf_gene=M;aa_name=p.D3N;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=M;protein=M;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26577	26577	.	+	.	ID=ID_177;Name=Q19E;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C55G;mat_pep_desc=;mat_pep_id=;vcf_gene=M;aa_name=p.Q19E;mutation_type=MISSENSE;ao=189;Variant_seq=G;ro=0;mat_pep_acc=;dp=189;chrom_region=M;protein=M;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26709	26709	.	+	.	ID=ID_178;Name=A63T;Reference_seq=G;ps_exc=ambiguous,amended;ps_filter=caution;nt_name=g.G187A;mat_pep_desc=;mat_pep_id=;vcf_gene=M;aa_name=p.A63T;mutation_type=MISSENSE;ao=189;Variant_seq=A;ro=0;mat_pep_acc=;dp=189;chrom_region=M;protein=M;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26858	26858	.	+	.	ID=ID_179;Name=F112F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C336T;mat_pep_desc=;mat_pep_id=;vcf_gene=M;aa_name=p.F112F;mutation_type=SILENT;ao=6;Variant_seq=T;ro=183;mat_pep_acc=;dp=189;chrom_region=M;protein=M;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.031746031746031744;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	26879	26879	.	+	.	ID=ID_180;Name=L119L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T357C;mat_pep_desc=;mat_pep_id=;vcf_gene=M;aa_name=p.L119L;mutation_type=SILENT;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=M;protein=M;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27213	27213	.	+	.	ID=ID_181;Name=L4L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C12T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF6;aa_name=p.L4L;mutation_type=SILENT;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF6;protein=ORF6;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27321	27321	.	+	.	ID=ID_182;Name=L40F;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A120T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF6;aa_name=p.L40F;mutation_type=MISSENSE;ao=42;Variant_seq=T;ro=147;mat_pep_acc=;dp=189;chrom_region=ORF6;protein=ORF6;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2222222222222222;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27493	27493	.	+	.	ID=ID_183;Name=P34S;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C100T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF7a;aa_name=p.P34S;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF7a;protein=ORF7a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27630	27630	.	+	.	ID=ID_184;Name=A79A;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C237T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF7a;aa_name=p.A79A;mutation_type=SILENT;ao=2;Variant_seq=T;ro=187;mat_pep_acc=;dp=189;chrom_region=ORF7a;protein=ORF7a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27697	27697	.	+	.	ID=ID_185;Name=L102F;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C304T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF7a;aa_name=p.L102F;mutation_type=MISSENSE;ao=4;Variant_seq=T;ro=184;mat_pep_acc=;dp=188;chrom_region=ORF7a;protein=ORF7a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02127659574468085;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27807	27807	.	+	.	ID=ID_186;Name=L18L;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C52T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF7b;aa_name=p.L18L;mutation_type=SILENT;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=ORF7b;protein=n/a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27860	27860	.	+	.	ID=ID_187;Name=Q35Q;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A105G;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF7b;aa_name=p.Q35Q;mutation_type=SILENT;ao=1;Variant_seq=G;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF7b;protein=n/a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	27889	27889	.	+	.	ID=ID_188;Name=g.C-5T;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C-5T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF8;aa_name=;mutation_type=;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	28251	28251	.	+	.	ID=ID_189;Name=I121fs;Reference_seq=TTCAT;ps_exc=;ps_filter=;nt_name=g.361delA;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF8;aa_name=p.I121fs;mutation_type=;ao=9;Variant_seq=GTTCT;ro=178;mat_pep_acc=;dp=189;chrom_region=ORF8;protein=ORF8;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.047619047619047616;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	28251	28251	.	+	.	ID=ID_190;Name=FI120VL;Reference_seq=TTCAT;ps_exc=;ps_filter=;nt_name=g.TTCA358_361GTTC;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF8;aa_name=p.FI120VL;mutation_type=;ao=2;Variant_seq=TTCT;ro=178;mat_pep_acc=;dp=189;chrom_region=ORF8;protein=ORF8;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010582010582010581;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	28271	28271	.	+	.	ID=ID_191;Name=g.A-3T;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A-3T;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=;mutation_type=;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	28311	28311	.	+	.	ID=ID_192;Name=P13L;Reference_seq=CC;ps_exc=;ps_filter=;nt_name=g.CC38_39TT;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.P13L;mutation_type=;ao=189;Variant_seq=TT;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	28311	28311	.	+	.	ID=ID_192;Name=P13L;Reference_seq=CC;ps_exc=;ps_filter=;nt_name=g.CC38_39TT;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.P13L;mutation_type=;ao=189;Variant_seq=TT;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	28361	28361	.	+	.	ID=ID_193;Name=E31_S33del;Reference_seq=GGAGAACGCAG;ps_exc=;ps_filter=;nt_name=g.90_98delAGAACGCAG;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.E31_S33del;mutation_type=;ao=189;Variant_seq=GG;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	28382	28382	.	+	.	ID=ID_194;Name=S37P;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T109C;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.S37P;mutation_type=MISSENSE;ao=1;Variant_seq=C;ro=188;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	28681	28681	.	+	.	ID=ID_195;Name=E136D;Reference_seq=G;ps_exc=;ps_filter=;nt_name=g.G408T;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.E136D;mutation_type=MISSENSE;ao=189;Variant_seq=T;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	complex	28881	28881	.	+	.	ID=ID_196;Name=RG203KR;Reference_seq=GGG;ps_exc=;ps_filter=;nt_name=g.GGG608_610AAC;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.RG203KR;mutation_type=;ao=189;Variant_seq=AAC;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	28963	28963	.	+	.	ID=ID_197;Name=L230L;Reference_seq=T;ps_exc=;ps_filter=;nt_name=g.T690A;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.L230L;mutation_type=SILENT;ao=27;Variant_seq=A;ro=162;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.14285714285714285;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	29409	29409	.	+	.	ID=ID_198;Name=T379I;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C1136T;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.T379I;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. ;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	29510	29510	.	+	.	ID=ID_199;Name=S413R;Reference_seq=A;ps_exc=;ps_filter=;nt_name=g.A1237C;mat_pep_desc=;mat_pep_id=;vcf_gene=N;aa_name=p.S413R;mutation_type=MISSENSE;ao=189;Variant_seq=C;ro=0;mat_pep_acc=;dp=189;chrom_region=N;protein=N;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	29555	29555	.	+	.	ID=ID_200;Name=g.C-3T;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C-3T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF10;aa_name=;mutation_type=;ao=29;Variant_seq=T;ro=160;mat_pep_acc=;dp=189;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.15343915343915343;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	snp	29627	29627	.	+	.	ID=ID_201;Name=R24C;Reference_seq=C;ps_exc=;ps_filter=;nt_name=g.C70T;mat_pep_desc=;mat_pep_id=;vcf_gene=ORF10;aa_name=p.R24C;mutation_type=MISSENSE;ao=1;Variant_seq=T;ro=188;mat_pep_acc=;dp=189;chrom_region=ORF10;protein=ORF10;sample_size=189;clade_defining=False;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005291005291005291;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	del	29733	29733	.	+	.	ID=ID_202;Name=g.CGAGGCCACGCGGAGTACGATCGAGTGT29733CT;Reference_seq=CGAGGCCACGCGGAGTACGATCGAGTGT;ps_exc=;ps_filter=;nt_name=g.CGAGGCCACGCGGAGTACGATCGAGTGT29733CT;mat_pep_desc=;mat_pep_id=;vcf_gene=intergenic;aa_name=;mutation_type=;ao=15;Variant_seq=CT;ro=0;mat_pep_acc=;dp=15;chrom_region=intergenic;protein=n/a;sample_size=189;clade_defining=True;viral_lineage=CZ.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=n/a;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
